OrbiMed’s Viatris VTRS Stock Holding History

OrbiMed’s Portfolio VTRS Stock Details VTRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-250,000	Closed	-$10.3M	–	155
2018 Q1	$10.3M	Buy	+250,000	New	+$10.7M	0.13%	103
2014 Q3	–	Sell	-100,000	Closed	-$5.16M	–	144
2014 Q2	$5.16M	Sell	100,000 -100,000	-50%	-$4.91M	0.06%	110
2014 Q1	$9.77M	Buy	+200,000	New	+$9.71M	0.12%	93
2013 Q3	–	Sell	-300,000	Closed	-$9.31M	–	133
2013 Q2	$9.31M	Buy	+300,000	New	+$8.96M	0.2%	80

Other funds holding VTRS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed's VTRS Position: Q1 2021 in Review

OrbiMed sold out of Viatris (VTRS) in Q1 2021, closing a stake of 535,149 shares — an estimated $10M sold.

OrbiMed first reported a position in VTRS in Q2 2013 and held it in 19 quarters. The position peaked at $204M in Q2 2014. 1,115 funds tracked by Wall St. Rank hold VTRS as of Q1 2021.

OrbiMed reported no remaining Viatris position as of Q1 2021 after selling out during the quarter.
OrbiMed sold 535,149 Viatris shares in Q1 2021, an estimated $10M.
OrbiMed first reported a position in Viatris in Q2 2013 and held it in 19 quarters.
OrbiMed's Viatris position peaked at $204M in Q2 2014.
1,115 funds tracked by Wall St. Rank held Viatris as of Q1 2021.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.